HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintains an $11 price target.
June 26, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on G1 Therapeutics and maintains an $11 price target.
The reaffirmed Buy rating and maintained price target by HC Wainwright & Co. analyst Edward White indicates a positive outlook for G1 Therapeutics. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100